Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients.

[1]  A. Telenti,et al.  Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals , 2013, Pharmacogenetics and genomics.

[2]  J. Vingerhoets,et al.  Similar Predictions of Etravirine Sensitivity Regardless of Genotypic Testing Method Used: Comparison of Available Scoring Systems , 2012, Antiviral therapy.

[3]  Namandjé N. Bumpus,et al.  Biotransformation of the Antiretroviral Drug Etravirine: Metabolite Identification, Reaction Phenotyping, and Characterization of Autoinduction of Cytochrome P450-Dependent Metabolism , 2012, Drug Metabolism and Disposition.

[4]  J. Mrus,et al.  Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial , 2012, AIDS research and treatment.

[5]  Reyes Martín-Peña,et al.  Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients. , 2012, The Journal of antimicrobial chemotherapy.

[6]  B. Gazzard,et al.  Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results , 2011, AIDS.

[7]  A. Lazzarin,et al.  Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. , 2011, The Journal of antimicrobial chemotherapy.

[8]  A. Lazzarin,et al.  Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine. , 2011, Journal of acquired immune deficiency syndromes.

[9]  E. Snoeck,et al.  Pharmacokinetics and Pharmacodynamics of the Non‐Nucleoside Reverse‐Transcriptase Inhibitor Etravirine in Treatment‐Experienced HIV‐1‐Infected Patients , 2010, Clinical pharmacology and therapeutics.

[10]  R. Haubrich,et al.  Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials , 2010, Antiviral therapy.

[11]  A. Telenti,et al.  Pharmacogenetics‐Based Population Pharmacokinetic Analysis of Efavirenz in HIV‐1‐Infected Individuals , 2009, Clinical pharmacology and therapeutics.

[12]  A. D’Avolio,et al.  An HPLC-PDA Method for the Simultaneous Quantification of the HIV Integrase Inhibitor Raltegravir, the New Nonnucleoside Reverse Transcriptase Inhibitor Etravirine, and 11 Other Antiretroviral Agents in the Plasma of HIV-Infected Patients , 2008, Therapeutic drug monitoring.

[13]  V. Vyncke,et al.  Effects of Different Meal Compositions and Fasted State on the Oral Bioavailability of Etravirine , 2008, Pharmacotherapy.

[14]  P. Vitiello,et al.  Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. , 2011, The Journal of antimicrobial chemotherapy.